← Human Trials & Peer-Reviewed Studies

Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia

Plain-language guide to PMID 18548234 (2008): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide) in 10 adults.

Key Facts

PMID
18548234
Journal
Psychopharmacology
Year
2008
Study type
Randomized Controlled Trial
Authors
Jubelt LE et al. (6 authors)
DOI
10.1007/s00213-008-1133-8
Registered trial
NCT00383747

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).

Who Took Part

The abstract describes 10 adults taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Participants were nonsmokers in order to avoid confounding effects of nicotine withdrawal and reinstatement on memory.

At each of two study visits, participants performed a test of episodic memory before and 4 h after application of a 14-mg transdermal nicotine (or identical placebo) patch in counterbalanced order.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the adults and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some adults received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Arousal, Attention, Mental Recall, Neuropsychological Tests, Nicotine and Psychotic Disorders.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 10 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.